101 results
Page 4 of 6
8-K
EX-99.1
7jdgh
14 Dec 20
Regulation FD Disclosure
7:30am
8-K
EX-99.1
hzjx2olmga8zdupb
5 Nov 20
Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update
7:31am
8-K
EX-99.1
u7t5loxnekiet8hm
4 Aug 20
Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update
4:47pm
8-K
EX-99.1
8n7ud7s
29 May 20
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader
7:06am
8-K
EX-99.2
7rw34 o1xurq2
29 May 20
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader
7:06am
8-K
knmik9qe
29 May 20
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader
7:06am
8-K
dt1tmwx4pyr8xug8vyw3
14 May 20
Other Events
12:00am
8-K
EX-99.1
u4sixyph
16 Mar 20
Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
9:01am
8-K
EX-1.1
nmtalu4jbgct
12 Nov 19
Arvinas, Inc. Announces Pricing of Public Offering of Common Stock
4:02pm
424B5
4ooamg5qsh7 djf5
7 Nov 19
Prospectus supplement for primary offering
4:05pm
424B5
n6ok 3bprwkol
6 Nov 19
Prospectus supplement for primary offering
5:31pm
8-K
EX-99.1
j15xlf2uh8zptvsk
4 Nov 19
Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update
5:10pm
8-K
EX-99.2
b8j73 2sbrs
23 Oct 19
Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders
6:39am
8-K
EX-99.1
0s3581a0a
23 Oct 19
Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders
6:39am